Markets continue to push higher.
In fact, since the start of the year, the Dow Jones is now up nearly 2,000 points. The NASDAQ tacked on 800 points on upside, as the S&P 500 jumped just over 300 points.
And we could see a considerable amount of further upside, as the U.S. considers eliminating some are all of the tariff on China, reports The Wall Street Journal. Treasury Secretary Steven Mnuchin is pushing for tariffs of $250 billion worth of Chinese goods to be stopped.
Should we see progress, we could see a monumental move in the markets.
While we wait to see what happens next, here are some of the hot stocks to watch.
Hot Stock No. 1 – Aurora Cannabis (ACB)
Analysts at Piper Jaffray say the market for legal cannabis could be worth $15 billion to $50 billion a year, with global sales growing to $250 billion to $500 billion. Analysts at Cowen believe U.S. cannabis sales alone could reach $80 billion by 2030 — an increase of $5 billion from earlier estimates, and a 4% compound annual growth rate.
Congress is getting behind legalization, too. Representative Earl Blumenauer just introduced the bill, which is designed to remove marijuana from under the Controlled Substances Act and allow it to be taxed and regulated like alcohol at the federal level. “Our federal marijuana laws are outdated, out of touch and have negatively impacted countless lives,” Blumenauer says, as quoted by USA Today. “Congress cannot continue to be out of touch with a movement that a growing majority of Americans support. It’s time to end this senseless prohibition.”
Aurora could be a standout trade, as the company now anticipates revenue for the quarter ended in December 2018 of between $50 million and $55 million, compared to $11.7 million year over year. That implies growth of nearly 330% in a single year. “Revenue growth for the quarter was driven by the Company’s strong position in the adult consumer use market in Canada, continued shipments of medical cannabis to Aurora’s expanding base of approximately 71,000 patients in Canada, and relatively stable, supply restricted shipments, to its growing international markets,” according to the company.
Hot Stock No. 2 — Axsome Therapeutics Inc. (NASDAQ:AXSM)
Axsome is a clinical stage biopharmaceutical company that is developing novel therapies for central nervous system (CNS) disorders. Even after exploding in recent weeks, there’s still plenty of opportunity in AXSM. The price is pushing higher in response to positive clinical data regarding one of its depression drugs, AXS-05, which significantly improved depression symptoms after six months, when compared with bupropion. The drug was also deemed to be safe and well-tolerated with no serious side effects.
“The clinically meaningful improvements in depressive symptoms seen with AXS-05 in this study were achieved versus an active comparator that is a well-established antidepressant, as early as only one week after initiation of treatment,” said Professor Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, Massachusetts General Hospital (MGH) and Associate Dean for Clinical & Translational Research, Harvard Medical School. “Data show currently marketed antidepressants fail to provide adequate treatment response in about two thirds of treated patients. An estimated 16 million Americans suffer from major depressive disorder each year. As an oral NMDA receptor antagonist with multimodal activity, AXS-05 could provide a new approach to treating this potentially life-threatening condition.”
Hot Stock No. 3 – Square Inc. (SQ)
As 2019 begins, we believe Square is one of the must-own stocks of the year. Granted, last year wasn’t it’s finest and we were knocked out of a previous trade, but it’s got a lot going for it. For one, third quarter revenue was up 51% year over year. Adjusted revenue was up 68%. That’s up from growth rates of 48% and 60% in the second quarter.
Analysts are taking advantage of the pullback, too. Canaccord Genuity for example just upgraded SQ to a Buy from a Hold, noting they had “been on the wrong side of Square stock for some time,” as noted by Barron’s. The firms also noted it sees a long-term opportunity given Square’s status as a “truly disruptive company.”